摘要
ATP柠檬酸裂解酶(ACLY))是与葡萄糖代谢相关的脂质形成过程中一个重要的酶,可催化转化柠檬酸变成草酰乙酸(OAA)和乙酰辅酶A。膜形成时脂质的合成需要获得期间的乙酰辅酶a、以及组蛋白乙酰化反应调节某些蛋白的表达异常增生的癌细胞。研究显示ACLY在肿瘤发生的作用是通过激活Akt蛋白激酶信号增加了酶的水平从而增加代谢活动。进一步的证据表明参与脂质生物合成的酶在癌症细胞增殖和进展过程中发挥重要作用。在许多癌症类型如胶质母细胞瘤、结直肠癌、乳腺癌、非小细胞肺癌、肝癌等;发现与正常细胞相比ACLY的水平相当高。癌症细胞生长相关的ACLY超表达可以用化学抑制剂或抑制ace基因进行抑制。抑制 ACLY导致癌症细胞代谢的变化,促进肿瘤的生长和扩散。本文总结了 ACLY在癌症发展和其抑制剂治疗癌症的作用。
关键词: 乙酰辅酶a
Current Drug Targets
Title:ATP Citrate Lyase (ACLY): A Promising Target for Cancer Prevention and Treatment
Volume: 16 Issue: 2
Author(s): Amrita Devi Khwairakpam, Mayengbam Singh Shyamananda, Bethsebie Lalduhsaki Sailo, Sivakumar Raju Rathnakaram, Ganesan Padmavathi, Jibon Kotoky and Ajaikumar B. Kunnumakkara
Affiliation:
关键词: 乙酰辅酶a
摘要: ATP citrate lyase (ACLY), an important enzyme involved in lipid biogenesis linked with glucose metabolism, catalyzes the conversion of citrate to oxaloacetic acid (OAA) and acetyl-CoA. The obtained acetyl-CoA is required for lipid synthesis during membrane biogenesis, as well as for histone acetylation reactions to regulate the expression of certain proteins in aberrantly proliferating cancer cells. Studies have shown a role for ACLY in tumorigenesis whereby increased levels of the enzyme leads to increased metabolic activity via activation of Akt signaling. Increasing lines of evidence suggest that enzymes involved in lipid biogenesis play a significant role in cancer cell proliferation and progression. In many cancer types such as glioblastoma, colorectal cancer, breast cancer, non-small cell lung cancer, hepatocellular carcinoma etc., the level of ACLY has been found to be quite high as compared to normal cells. Cancer cell growth related to overexpression of ACLY can be inhibited by using chemical inhibitors or by the knockdown of ACLY gene. Inhibition of ACLY leads to changes in cancer cell metabolism that promotes tumor growth and proliferation. This review summarizes the role of ACLY in cancer development and its inhibitors in cancer treatment.
Export Options
About this article
Cite this article as:
Amrita Devi Khwairakpam , Mayengbam Singh Shyamananda , Bethsebie Lalduhsaki Sailo , Sivakumar Raju Rathnakaram , Ganesan Padmavathi , Jibon Kotoky and Ajaikumar B. Kunnumakkara , ATP Citrate Lyase (ACLY): A Promising Target for Cancer Prevention and Treatment, Current Drug Targets 2015; 16 (2) . https://dx.doi.org/10.2174/1389450115666141224125117
DOI https://dx.doi.org/10.2174/1389450115666141224125117 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
High Expression of SIRT1 Associates with the Doxorubicin Resistance of Breast Cancer through the Activation of Akt
Anti-Cancer Agents in Medicinal Chemistry Potential Usage of ING Family Members in Cancer Diagnostics and Molecular Therapy
Current Drug Targets Methotrexate: A Drug of the Future in Ulcerative Colitis?
Current Drug Targets Bitter Gourd (Momordica charantia) is a Cornucopia of Health: A Review of its Credited Antidiabetic, Anti-HIV, and Antitumor Properties
Current Molecular Medicine Cerebrovascular and Blood-Brain Barrier Morphology in Spontaneously Hypertensive Rats: Effect of Treatment with Choline Alphoscerate
CNS & Neurological Disorders - Drug Targets Tyrosine Kinase Inhibitors Gefitinib, Lapatinib and Sorafenib Induce Rapid Functional Alterations in Breast Cancer Cells
Current Cancer Drug Targets Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation Molecular Pathology and Molecular Markers of Ductal Carcinoma in-situ
Current Cancer Therapy Reviews The Gene Expression Profiles of Medulloblastoma Cell Lines Resistant to Preactivated Cyclophosphamide
Current Cancer Drug Targets Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities
Current Medicinal Chemistry Defensin Participation in Innate and Adaptive Immunity
Current Pharmaceutical Design Annexins Bend Wound Edges during Plasma Membrane Repair
Current Medicinal Chemistry Oncogene-Blocking Therapies: New Insights from Conditional Mouse Tumor Models
Current Cancer Drug Targets Microbial Biotransformation: Recent Developments on Steroid Drugs
Recent Patents on Biotechnology Cytokines: From Gut Inflammation to Colorectal Cancer
Current Drug Targets Mesoporous Materials Used in Medicine and Environmental Applications
Current Topics in Medicinal Chemistry Renal Cell Carcinoma Cancer Stem Cells as Therapeutic Targets
Current Signal Transduction Therapy Retinoids as Differentiating Agents in Oncology: A Network of Interactions with Intracellular Pathways as the Basis for Rational Therapeutic Combinations
Current Pharmaceutical Design Benzo[d]imidazol-5-yl)-5-(substituted)-1,3,4-Oxadiazoles: Synthesis, Anticancer, Antimicrobial and In Silico Studies
Letters in Drug Design & Discovery Separation of Ginseng Active Ingredients and their Roles in Cancer Metastasis Supplementary Therapy
Current Drug Metabolism